Monte Rosa Therapeutics Stock Piotroski F Score
| GLUE Stock | USD 8.49 0.14 1.68% |
Monte | Piotroski F Score |
At this time, it appears that Monte Rosa's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | No Change |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | No Change |
Monte Rosa Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Monte Rosa is to make sure Monte is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Monte Rosa's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Monte Rosa's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 26.9 M | 46.6 M |
|
| |||||
| Non Current Liabilities Total | 46.9 M | 77.9 M |
|
| |||||
| Total Assets | 236 M | 303.8 M |
|
| |||||
| Total Current Assets | 201.1 M | 236.2 M |
|
|
Monte Rosa Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Monte Rosa's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Monte Rosa in a much-optimized way.
| -0.78 | 0.61 | 0.21 | 0.98 | 0.99 | -0.92 | ||
| -0.78 | -0.28 | 0.19 | -0.69 | -0.76 | 0.49 | ||
| 0.61 | -0.28 | 0.89 | 0.75 | 0.71 | -0.7 | ||
| 0.21 | 0.19 | 0.89 | 0.39 | 0.32 | -0.42 | ||
| 0.98 | -0.69 | 0.75 | 0.39 | 0.99 | -0.94 | ||
| 0.99 | -0.76 | 0.71 | 0.32 | 0.99 | -0.93 | ||
| -0.92 | 0.49 | -0.7 | -0.42 | -0.94 | -0.93 |
Click cells to compare fundamentals
About Monte Rosa Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
Monte Rosa ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Monte Rosa's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Monte Rosa's managers, analysts, and investors.Environmental | Governance | Social |
About Monte Rosa Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Monte Rosa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monte Rosa using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monte Rosa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:Check out Monte Rosa Altman Z Score, Monte Rosa Correlation, Monte Rosa Valuation, as well as analyze Monte Rosa Alpha and Beta and Monte Rosa Hype Analysis. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.